Literature DB >> 28487551

High-free androgen index is associated with increased risk of non-alcoholic fatty liver disease in women with polycystic ovary syndrome, independent of obesity and insulin resistance.

J Cai1, C H Wu2, Y Zhang1, Y Y Wang1, W D Xu1, T C Lin1, S X Li1, L H Wang1, J Zheng1, Y Sun3, W Liu1, T Tao1.   

Abstract

BACKGROUND/
OBJECTIVE: Central obesity and insulin resistance (IR) are common conditions in women with polycystic ovary syndrome (PCOS) and in subjects with non-alcoholic fatty liver disease (NAFLD). However, few studies have addressed the association between hyperandrogenism (HA) and NAFLD. We aimed to determine whether variations in the free androgen index (FAI) might be associated with NAFLD prevalence. SUBJECTS/
METHODS: A cross-sectional study was performed including 400 Chinese women with PCOS and 100 age, and body mass index (BMI)-matched women. The anthropometric and serum biochemical parameters related to sex steroids, glucose and lipid profiles were examined. Liver fat content (LFC) was measured by quantitative ultrasound.
RESULTS: The prevalence of NAFLD was 56.23% in PCOS patients and 38% in controls (P=0.001), and this prevalence increased with FAI quartile independently of obesity and homeostasis model assessment of insulin resistance (HOMA-IR). The FAI level increased from non-NAFLD group to NAFLD group. The FAI was positively associated with the metabolic parameters LFC, BMI, waist circumference, alanine aminotransferases, aspartate, triglyceride, total cholesterol and low-density lipoprotein cholesterol, and was negatively associated with high-density lipoprotein. Moreover, in multivariate logistic regression analysis BMI, high-sensitivity C-reactive protein (hsCRP), FAI, LFC and HOMA-IR were significantly associated with NAFLD. The cut-off values of FAI, LFC, BMI and hsCRP to predict NAFLD were 9.86%, 17.19%, 24.38% and 0.72%, respectively. The area under the curve for predicting NAFLD in PCOS patients showed comparable sensitivity and specificity between BMI and a new index combining FAI with hsCRP.
CONCLUSIONS: A higher FAI level is associated with increased LFC and NAFLD prevalence independent of obesity and IR.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28487551     DOI: 10.1038/ijo.2017.116

Source DB:  PubMed          Journal:  Int J Obes (Lond)        ISSN: 0307-0565            Impact factor:   5.095


  37 in total

1.  Androgen receptor-mediated antagonism of estrogen-dependent low density lipoprotein receptor transcription in cultured hepatocytes.

Authors:  G E Croston; L B Milan; K B Marschke; M Reichman; M R Briggs
Journal:  Endocrinology       Date:  1997-09       Impact factor: 4.736

2.  Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease.

Authors:  H Kahal; G Abouda; A S Rigby; A M Coady; E S Kilpatrick; S L Atkin
Journal:  Clin Endocrinol (Oxf)       Date:  2013-12-12       Impact factor: 3.478

Review 3.  Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options.

Authors:  Konstantinos Tziomalos; Vassilios G Athyros; Asterios Karagiannis
Journal:  Curr Vasc Pharmacol       Date:  2012-03       Impact factor: 2.719

4.  Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

Authors:  M Matsuda; R A DeFronzo
Journal:  Diabetes Care       Date:  1999-09       Impact factor: 19.112

5.  Abnormal aminotransferase activity in women with polycystic ovary syndrome.

Authors:  Jeffrey B Schwimmer; Omid Khorram; Vicki Chiu; Walter B Schwimmer
Journal:  Fertil Steril       Date:  2005-02       Impact factor: 7.329

Review 6.  Evidence and recommendations for imaging liver fat in children, based on systematic review.

Authors:  Hannah I Awai; Kimberly P Newton; Claude B Sirlin; Cynthia Behling; Jeffrey B Schwimmer
Journal:  Clin Gastroenterol Hepatol       Date:  2013-09-30       Impact factor: 11.382

7.  Endocrine factors associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome: do androgens play a role?

Authors:  Robert P Kauffman; Teresa E Baker; Vicki Baker; Michele M Kauffman; V Daniel Castracane
Journal:  Gynecol Endocrinol       Date:  2010-01       Impact factor: 2.260

8.  Assessment of liver fat content using quantitative ultrasonography to evaluate risks for metabolic diseases.

Authors:  Ming-Feng Xia; Hua Bian; Hong-Mei Yan; Huan-Dong Lin; Xin-Xia Chang; Xiao-Ming Li; Hui Ma; Wan-Yuan He; Nai-Qing Zhao; Pu Xia; Xin Gao
Journal:  Obesity (Silver Spring)       Date:  2015-08-04       Impact factor: 5.002

9.  The prevalence and etiology of elevated aminotransferase levels in the United States.

Authors:  Jeanne M Clark; Frederick L Brancati; Anna Mae Diehl
Journal:  Am J Gastroenterol       Date:  2003-05       Impact factor: 10.864

10.  Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004.

Authors:  Abigail Fraser; Matthew P Longnecker; Debbie A Lawlor
Journal:  Gastroenterology       Date:  2007-09-02       Impact factor: 22.682

View more
  17 in total

Review 1.  Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis.

Authors:  A L L Rocha; L C Faria; T C M Guimarães; G V Moreira; A L Cândido; C A Couto; F M Reis
Journal:  J Endocrinol Invest       Date:  2017-06-13       Impact factor: 4.256

2.  Low Serum 25-Hydroxyvitamin D Levels Are Associated With Hyperandrogenemia in Polycystic Ovary Syndrome: A Cross-Sectional Study.

Authors:  Chang Shan; Yu-Chen Zhu; Jie Yu; Yi Zhang; Yu-Ying Wang; Nan Lu; Jie Cai; Wei Liu; Tao Tao
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-02       Impact factor: 6.055

Review 3.  The Hepatoprotective and Hepatotoxic Roles of Sex and Sex-Related Hormones.

Authors:  Linlin Xu; Yuan Yuan; Zhaodi Che; Xiaozhi Tan; Bin Wu; Cunchuan Wang; Chengfang Xu; Jia Xiao
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

4.  Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database.

Authors:  Balachandran Kumarendran; Michael W O'Reilly; Konstantinos N Manolopoulos; Konstantinos A Toulis; Krishna M Gokhale; Alice J Sitch; Chandrika N Wijeyaratne; Arri Coomarasamy; Wiebke Arlt; Krishnarajah Nirantharakumar
Journal:  PLoS Med       Date:  2018-03-28       Impact factor: 11.069

Review 5.  Sex Hormone-Binding Globulin (SHBG) as an Early Biomarker and Therapeutic Target in Polycystic Ovary Syndrome.

Authors:  Xianqin Qu; Richard Donnelly
Journal:  Int J Mol Sci       Date:  2020-11-01       Impact factor: 5.923

6.  Non-alcoholic fatty liver disease in polycystic ovary syndrome women.

Authors:  Young Bin Won; Seok Kyo Seo; Bo Hyon Yun; SiHyun Cho; Young Sik Choi; Byung Seok Lee
Journal:  Sci Rep       Date:  2021-03-29       Impact factor: 4.379

Review 7.  NAFLD and NASH in Postmenopausal Women: Implications for Diagnosis and Treatment.

Authors:  Johanna K DiStefano
Journal:  Endocrinology       Date:  2020-10-01       Impact factor: 4.736

8.  A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: an update meta-analysis.

Authors:  Jia Wu; Xin-Yu Yao; Ru-Xia Shi; Su-Fen Liu; Xiao-Yong Wang
Journal:  Reprod Health       Date:  2018-05-10       Impact factor: 3.223

9.  Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies.

Authors:  Miguel A Sanchez-Garrido; Manuel Tena-Sempere
Journal:  Mol Metab       Date:  2020-02-05       Impact factor: 7.422

10.  Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome.

Authors:  Mohammad Maysara Asfari; Muhammad Talal Sarmini; Firas Baidoun; Yasser Al-Khadra; Yamen Ezzaizi; Srinivasan Dasarathy; Arthur McCullough
Journal:  BMJ Open Gastroenterol       Date:  2020-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.